Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis

医学 脂肪性肝炎 肝活检 肝硬化 脂肪肝 内科学 安慰剂 脂肪变性 临床试验 纤维化 胃肠病学 活检 病理 疾病 替代医学
作者
Stephen A. Harrison,Vlad Ratziu,Quentin M. Anstee,Mazen Noureddin,Arun J. Sanyal,Jörn M. Schattenberg,Pierre Bédossa,Mustafa R. Bashir,David J. Schneider,Rebecca Taub,Meena B. Bansal,Kris V. Kowdley,Zobair M. Younossi,Rohit Loomba
出处
期刊:Alimentary Pharmacology & Therapeutics [Wiley]
卷期号:59 (1): 51-63 被引量:67
标识
DOI:10.1111/apt.17734
摘要

Summary Background Non‐alcoholic steatohepatitis (NASH) is a progressive form of non‐alcoholic fatty liver disease (NAFLD) associated with steatosis, hepatocellular injury, inflammation and fibrosis. In a Phase 2 trial in adults with NASH (NCT02912260), resmetirom, an orally administered, liver‐targeted thyroid hormone receptor‐β selective agonist, significantly reduced hepatic fat (via imaging) and resolved NASH without worsening fibrosis (via liver biopsy) in a significant number of patients compared with placebo. Aims To present the design of the Phase 3 MAESTRO clinical programme evaluating resmetirom for treatment of NASH (MAESTRO‐NAFLD‐1 [NCT04197479], MAESTRO‐NAFLD‐OLE [NCT04951219], MAESTRO‐NASH [NCT03900429], MAESTRO‐NASH‐OUTCOMES [NCT05500222]). Methods MAESTRO‐NASH is a pivotal serial biopsy trial in up to 2000 adults with biopsy‐confirmed at‐risk NASH. Patients are randomised to a once‐daily oral placebo, 80 mg resmetirom, or 100 mg resmetirom. Liver biopsies are conducted at screening, week 52 and month 54. MAESTRO‐NAFLD‐1 is a 52‐week safety trial in ~1400 adults with NAFLD/presumed NASH (based on non‐invasive testing); ~700 patients from MAESTRO‐NAFLD‐1 are enrolled in MAESTRO‐NAFLD‐OLE, a 52‐week active treatment extension to further evaluate safety. MAESTRO‐NASH‐OUTCOMES is enrolling 700 adults with well‐compensated NASH cirrhosis to evaluate the potential for resmetirom to slow progression to hepatic decompensation events. Non‐invasive tests (biomarkers, imaging) are assessed longitudinally throughout, in addition to validated patient‐reported outcomes. Conclusion The MAESTRO clinical programme was designed in conjunction with regulatory authorities to support approval of resmetirom for treatment of NASH. The surrogate endpoints, based on week 52 liver biopsy, serum biomarkers and imaging, are confirmed by long‐term clinical liver‐related outcomes in MAESTRO‐NASH (month 54) and MAESTRO‐NASH‐OUTCOMES (time to event).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
研友_VZG7GZ应助科研通管家采纳,获得10
刚刚
研友_VZG7GZ应助科研通管家采纳,获得10
刚刚
SciGPT应助科研通管家采纳,获得10
刚刚
情怀应助zzdd采纳,获得10
刚刚
SciGPT应助科研通管家采纳,获得10
刚刚
彭于晏应助科研通管家采纳,获得10
刚刚
彭于晏应助科研通管家采纳,获得10
刚刚
彭于晏应助科研通管家采纳,获得10
刚刚
彭于晏应助科研通管家采纳,获得10
刚刚
彭于晏应助科研通管家采纳,获得10
刚刚
刚刚
彭于晏应助科研通管家采纳,获得10
刚刚
完美世界应助科研通管家采纳,获得10
刚刚
完美世界应助科研通管家采纳,获得10
1秒前
1秒前
虚心的不二完成签到 ,获得积分10
1秒前
1秒前
1秒前
1秒前
思源应助科研通管家采纳,获得10
1秒前
思源应助科研通管家采纳,获得10
1秒前
WILAY889完成签到,获得积分10
1秒前
李健的粉丝团团长应助asd采纳,获得10
1秒前
1秒前
1秒前
科研通AI2S应助科研通管家采纳,获得10
1秒前
科研通AI2S应助科研通管家采纳,获得10
1秒前
FashionBoy应助科研通管家采纳,获得10
1秒前
FashionBoy应助科研通管家采纳,获得10
2秒前
天天快乐应助科研通管家采纳,获得10
2秒前
天天快乐应助科研通管家采纳,获得10
2秒前
无极微光应助科研通管家采纳,获得20
2秒前
无极微光应助科研通管家采纳,获得20
2秒前
2秒前
2秒前
李健应助科研通管家采纳,获得10
2秒前
李健应助科研通管家采纳,获得10
2秒前
2秒前
2秒前
丘比特应助科研通管家采纳,获得10
2秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics 3000
Les Mantodea de guyane 2500
Feldspar inclusion dating of ceramics and burnt stones 1000
What is the Future of Psychotherapy in a Digital Age? 801
The Psychological Quest for Meaning 800
Digital and Social Media Marketing 600
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5969782
求助须知:如何正确求助?哪些是违规求助? 7274494
关于积分的说明 15984743
捐赠科研通 5107184
什么是DOI,文献DOI怎么找? 2742896
邀请新用户注册赠送积分活动 1708018
关于科研通互助平台的介绍 1621114